Literature DB >> 8370158

Immune stimulatory and anti-tumour properties of haemin.

A Tsuji1, J Wang, K H Stenzel, A Novogrodsky.   

Abstract

IL-2 induces tumour regression in some patients with metastatic disease, but the dose of IL-2 is limited by severe toxicity. Agents that increase the expression of IL-2 receptors in the effector cells could be used to improve the effectiveness of IL-2 in mediating its anti-tumour effect. We have reported that haemin increased the expression of IL-2 receptors in human peripheral blood mononuclear cells (PBMC) and synergized with IL-2 in the induction of mitogenicity, cytotoxicity and cytokine production. We now report on haemin-induced immune stimulation and tumour regression in mice. Haemin-induced mitogenicity in mouse splenocytes was potentiated up to two-fold by IL-2. The combination of haemin and IL-2 was also effective in inducing cytotoxicity for natural killer (NK)-resistant target cells. Maximal induction of cytotoxicity was attained at an optimal concentration of haemin of 10 microM. Higher concentrations were less effective. Splenocytes isolated from mice that had been treated in vivo with haemin and IL-2 incorporated twice the amount of 3H-thymidine compared with splenocytes from mice treated with either haemin or IL-2 alone. Cytotoxicity of splenocytes for NK-resistant target cells was not increased following in vivo administration of haemin and IL-2 when fresh splenocytes were tested. Cytotoxicity was enhanced, however, up to five-fold following 48 h in vitro incubation with IL-2. Administration of haemin and IL-2 resulted in a significant decrease (40%) of established hepatic metastases in mice. Either IL-2 or haemin alone at the dose used were ineffective. The anti-tumour effect of haemin and IL-2 was enhanced (63% decrease in metastases) by administration of the thiol compound, N-acetylcysteine. Since haemin can safely be administered to patients, it may represent a new class of biologic response modifiers that could enhance IL-2-mediated anti-tumour effects.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8370158      PMCID: PMC1554895          DOI: 10.1111/j.1365-2249.1993.tb08177.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

Review 1.  Hematin therapy for the porphyric attack.

Authors:  C A Pierach
Journal:  Semin Liver Dis       Date:  1982-05       Impact factor: 6.115

Review 2.  Interleukin-2 toxicity.

Authors:  J P Siegel; R K Puri
Journal:  J Clin Oncol       Date:  1991-04       Impact factor: 44.544

3.  Anti-tumor properties of lymphocytes activated by the oxidizing mitogens.

Authors:  J Wang; M Suthanthiran; A Walle; M Lagman; R Schwartz; V Murthi; A Novogrodsky; K H Stenzel
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

4.  Haemin enhancement of glucose transport in human lymphocytes: stimulation of protein tyrosine phosphatase and activation of p56lck tyrosine kinase.

Authors:  H M Lander; D M Levine; A Novogrodsky
Journal:  Biochem J       Date:  1993-04-01       Impact factor: 3.857

5.  Mitogenic and co-mitogenic properties of hemin.

Authors:  K H Stenzel; A L Rubin; A Novogrodsky
Journal:  J Immunol       Date:  1981-12       Impact factor: 5.422

6.  A semi-automated micro-assay for H2O2 release by human blood monocytes and mouse peritoneal macrophages.

Authors:  J De la Harpe; C F Nathan
Journal:  J Immunol Methods       Date:  1985-04-22       Impact factor: 2.303

7.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

8.  A novel approach to the generation and identification of experimental hepatic metastases in a murine model.

Authors:  R Lafreniere; S A Rosenberg
Journal:  J Natl Cancer Inst       Date:  1986-02       Impact factor: 13.506

9.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

Authors:  J J Mulé; S Shu; S L Schwarz; S A Rosenberg
Journal:  Science       Date:  1984-09-28       Impact factor: 47.728

10.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

Authors:  S A Rosenberg; J J Mulé; P J Spiess; C M Reichert; S L Schwarz
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  2 in total

1.  Differences in resistance of C57BL/6 and C57BL/10 mice to infection by Mycobacterium avium are independent of gamma interferon.

Authors:  R Appelberg; I S Leal; T F Pais; J Pedrosa; M Flórido
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

2.  Heme oxygenase is not involved in the anti-proliferative effects of statins on pancreatic cancer cells.

Authors:  K Vanova; S Boukalova; H Gbelcova; L Muchova; J Neuzil; R Gurlich; T Ruml; L Vitek
Journal:  BMC Cancer       Date:  2016-05-12       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.